Expression of bcl-2 in breast cancer: correlation with clinicopathological characteristics and survival.
Breast cancer is the most common malignancy in women. It is an immensely heterogeneous disease, characterised by a broad variety of clinical development. The research in recent years has focused on finding new markers of prognosis. This study investigates the role of expression of the bcl-2 protein in breast cancer. We analysed bcl-2 expression in 57 women with primary breast carcinoma who were treated with neoadjuvant (primary) chemotherapy, followed by a surgical procedure. The bcl-2 expression was correlated with other clinicopathological characteristics of the tumour- histological grade, stage, expression of hormonal receptors, proliferation rate, and with the survival of the patients. No significant association of bcl-2 expression with either overall survival or disease free survival was found.
Cecka
Filip
F
Charles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Department of Surgery, Czech Republic. filip.cecka@seznam.cz
Hornychová
Helena
H
Melichar
Bohuslav
B
Ryska
Ales
A
Jandík
Pavel
P
Mergancová
Jindriska
J
Klozová-Urminská
Hana
H
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism; D015996:Survival Rate
D015415:Biomarkers; D019253:Proto-Oncogene Proteins c-bcl-2; D011960:Receptors, Estrogen